

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	_____1_____
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	_____3_____ _ Please refer to Item 2a and registration in the Chinese clinical trial registry, ChiCTR2000029869_
	2b	All items from the World Health Organization Trial Registration Data Set	_____15_____
Protocol version	3	Date and version identifier	_____16_____
Funding	4	Sources and types of financial, material, and other support	_____1,17,_18_____
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	_____1_____
	5b	Name and contact information for the trial sponsor	_____16_____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	_____11_____
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	

## Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	____3,4____ _
	6b	Explanation for choice of comparators	____3,4,5____
Objectives	7	Specific objectives or hypotheses	____5____
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	____5____

## Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	____5,6____ _
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	____6,7____
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	____8,9____
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	____7,____
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	____7____
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	____7,9____
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	____9,10____ _
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	____10,____Figure2____ _

Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	___8___
			<p>Patients will be recruited following admission to hospital for positive of SARS-CoV-2 nucleic acid testing ___ COVID-19 has strong infectious ability. Any patient who is identified will be isolated and treated. Till now, there is no specific drugs for COVID-19. _ The patients have high compliance. _</p>
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	

**Methods: Assignment of interventions (for controlled trials)**

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	___8___
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	___8___
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to	___8_

		interventions	
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	The design is open label with only assessors being blinded The unblinding will not occur
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	

**Methods: Data collection, management, and analysis**

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	__12__
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	__7__

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___12___
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	_10,11_____
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___10,11___
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_10,11_____

**Methods: Monitoring**

			NA, _ Since there's no high risk and secure problems in treating COVID-19 in this prescription, and because of the specialty of the pandemic, we didn't have sufficient conditions to set up Data Monitoring Committee (DMC) and other groups that with detailed division of labor._____
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details	

about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed

	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	____11____
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	____10____
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	____12, once a month____
<b>Ethics and dissemination</b>			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	____12____
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	____12____

Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	___ 13 ___
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	___ NA ___ The participant data and biological specimens are only intended for the clinical trial use
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	___ 11 ___
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	___ 15 ___
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	___ 12 ___
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	___ Informed Consent form ___
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	___ 11 ___
	31b	Authorship eligibility guidelines and any intended use of professional writers	___ 10 ___ <u>The datasets analysed during the current study are available from the corresponding author on reasonable request</u>
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	<u>reasonable request</u>
<b>Appendices</b>			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_ 15 _____

Biological

33

Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular

specimens

analysis in the current trial and for future use in ancillary studies, if applicable

\_\_NA\_\_  
Biological specimens may have potent infectious activity. We will not conduct genetic or molecular analysis in the current trial and for future use.

---